Natera Introduces Fetal RhD NIPT Test to Aid Physicians and Patients During RhIg Shortage
Shots:
- Natera has introduced its new cfDNA-based fetal RhD test aiding physicians and patients during Rho(D) immune globulin therapy (RhIg) shortages
- Natera’s test can be carried out as early as 9wks. gestation from the maternal blood to detect fetal RhD status such as complex pseudogene and RhD-CE-D hybrid variants
- The launch was supported by a validation study involving 650 RhD-ve pregnancies, confirming fetal RhD status using newborn serology and exhibiting a sensitivity & specificity of 100% & 99%, respectively. The results will be highlighted at ACOG's Annual Clinical & Scientific Meeting 2024
Ref: Natera | Image: Natera
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
